AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16411525 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 16411525 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 20
Study 16411525 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 20
Study 12846625 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40
Study 12846625 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular-blocking agent (NMB) with tracheal tube ventilation
Number of subjects: 40
Study 10804381 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 0
Study 8653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing (EEtv)
Number of subjects: 123
Study 8653145 — intervention group
Group type: COMPARATOR
Intervention: Resting metabolic rate (RMR)
Number of subjects: 123
Study 8653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected television viewing duration
Number of subjects: 123
Study 1506846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabular format
Number of subjects: 114
Study 1506846 — intervention group
Group type: COMPARATOR
Intervention: Graphics format
Number of subjects: 114
Study 1506846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Men)
Number of subjects: 114
Study 1506846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 114
Study 6492943 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg
Number of subjects: 30
Study 6492943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 30
Study 31868695 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation; 4 stimulations per day for 4 weeks.
Number of subjects: 19
Study 31868695 — intervention group
Group type: COMPARATOR
Intervention: Sham-device; 4 stimulations per day for 4 weeks.
Number of subjects: 19
Study 31868695 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation and Sham-device; measured with the 13C-octanoic acid breath test.
Number of subjects: 19
Study 30206110 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 195
Study 30206110 — intervention group
Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 195
Study 26418414 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSULE (50 mg)
Number of subjects: 12
Study 26418414 — intervention group
Group type: COMPARATOR
Intervention: TABLET (diclofenac sodium enteric-coated tablet)
Number of subjects: 12
Study 24831596 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diversion
Number of subjects: 0
Study 24831596 — intervention group
Group type: COMPARATOR
Intervention: Traditional endovascular coiling therapy
Number of subjects: 0
Study 22221615 — intervention group
Group type: EXPERIMENTAL
Intervention: PAB-F (pantoprazole 40mg-bid, amoxicillin 1g-bid, bismuth subcitrate 240mg-bid for 2 weeks, furazolidone 200mg-bid for the first week)
Number of subjects: 296
Study 22221615 — intervention group
Group type: COMPARATOR
Intervention: PA-CT (pantoprazole 40mg-bid for 10 days, amoxicillin 1g-bid for the first 5 days, clarithromycin 500mg-bid plus tinidazole 500mg-bid for the second 5 days)
Number of subjects: 296
Study 20460065 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (RSWT)
Number of subjects: 50
Study 20460065 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 17763897 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping (CON)
Number of subjects: 92
Study 17763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Invaginated stripping (INVAG)
Number of subjects: 92
Study 17763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 17590964 — intervention group
Group type: EXPERIMENTAL
Intervention: Music selected by the experimenter from the subject's preferred genre or artist (n = 30)
Number of subjects: 90
Study 17590964 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific song selected by the subject (n = 30)
Number of subjects: 90
Study 17590964 — intervention group
Group type: COMPARATOR
Intervention: No music (control group) (n = 30)
Number of subjects: 90
Study 10851943 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for ovarian cancer
Number of subjects: 0
Study 9358111 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oat colloidal grain suspension (0.007% and 0.7%)
Number of subjects: 65
Study 9358111 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rice colloidal grain suspension (0.007% and 0.7%)
Number of subjects: 65
Study 9358111 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent tests (RAST)
Number of subjects: 65
Study 8261678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (2 micrograms postdialysis three times per week)
Number of subjects: 11
Study 8261678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (2 micrograms postdialysis three times per week)
Number of subjects: 11
Study 8261678 — intervention group
Group type: COMPARATOR
Intervention: Both intravenous and oral calcitriol
Number of subjects: 11
Study 3486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 3486840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29967954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (20/3.75 mg, loading/maintenance dose) with aspirin (100 mg)
Number of subjects: 742
Study 29967954 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300/75 mg) with aspirin (100 mg)
Number of subjects: 742
Study 27562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea catechin beverage (570 mg)
Number of subjects: 16
Study 27562352 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 16
Study 24875045 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% augmented feedback
Number of subjects: 34
Study 24875045 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% augmented feedback
Number of subjects: 34
Study 24875045 — intervention group
Group type: COMPARATOR
Intervention: 0% augmented feedback
Number of subjects: 34
Study 22133704 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative bulky dressing for 2 weeks
Number of subjects: 94
Study 22133704 — intervention group
Group type: COMPARATOR
Intervention: Bandage removal at 48 to 72 hours with placement of an adhesive strip
Number of subjects: 94
Study 20182703 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin, 0.4 mg/day for 4 weeks
Number of subjects: 92
Study 17707382 — intervention group
Group type: EXPERIMENTAL
Intervention: P2RY12 haplotype H2
Number of subjects: 708
Study 17707382 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched white males free of vascular disease)
Number of subjects: 708
Study 17707382 — intervention group
Group type: EXPERIMENTAL
Intervention: P2RY12 variants or haplotype H2
Number of subjects: 708
Study 16184478 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest NAE quintile (most acidic)
Number of subjects: 27096
Study 16184478 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NAE levels among men who smoked for more than 45 years
Number of subjects: 27096
Study 16184478 — intervention group
Group type: COMPARATOR
Intervention: Lowest NAE quintile (least acidic)
Number of subjects: 27096
Study 12357146 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed intraoperative fluid administration (protocol group)
Number of subjects: 100
Study 12357146 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative care (control group)
Number of subjects: 100
Study 10479195 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based intravenous lipid emulsion (ILE)
Number of subjects: 18
Study 10479195 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based emulsion
Number of subjects: 18
Study 8562983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case manager
Number of subjects: 0
Study 8562983 — intervention group
Group type: COMPARATOR
Intervention: Conventional management by physicians
Number of subjects: 0
Study 1912556 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 1 year (n = 10)
Number of subjects: 18
Study 1912556 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 6 months (n = 6 after initial no-treatment)
Number of subjects: 18
Study 1912556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) (n = 8)
Number of subjects: 18
Study 1912556 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN treatment for 1 year
Number of subjects: 18
Study 1912556 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN treatment for 6 months
Number of subjects: 18
Study 1912556 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic scores after 12 months
Number of subjects: 18
Study 7036336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 0
Study 7036336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg daily)
Number of subjects: 0
Study 7036336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31987371 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT-inhibitors in combination with first-line chemotherapy
Number of subjects: 0
Study 28425253 — intervention group
Group type: COMPARATOR
Intervention: B2-G haplotype
Number of subjects: 1927
Study 28425253 — intervention group
Group type: COMPARATOR
Intervention: B2B2 genotype
Number of subjects: 1927
Study 28425253 — intervention group
Group type: COMPARATOR
Intervention: B2B2 genotype in males
Number of subjects: 1927
Study 28425253 — intervention group
Group type: COMPARATOR
Intervention: B2 allele
Number of subjects: 1927
Study 26019464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Three tablets (9 tablets/day) containing 2 mg of lactomin, 10 mg of Clostridium butyricum TO‐A, and 10 mg of Bacillus mesentericus TO‐A
Number of subjects: 60
Study 26019464 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (9 tablets/day)
Number of subjects: 60
Study 23553051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar jam
Number of subjects: 16
Study 23553051 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar jam
Number of subjects: 16
Study 23553051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar jam with antioxidant
Number of subjects: 16
Study 21760636 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigmatizing video
Number of subjects: 73
Study 21760636 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 73
Study 19430040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antioxidant Phenovin and immunomodulator Una de gato
Number of subjects: 0
Study 19430040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17380549 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group (conductive carbon polymer mattress used 2 hours before and after surgery)
Number of subjects: 103
Study 17380549 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group
Number of subjects: 103
Study 17380549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 15538131 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (800 to 1600 mg)
Number of subjects: 30
Study 15538131 — intervention group
Group type: COMPARATOR
Intervention: S-adenosyl-L-methionine
Number of subjects: 30
Study 11418543 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct physician order entry using the Medical Gopher system
Number of subjects: 11
Study 11418543 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper‐based ordering methods
Number of subjects: 11
Study 9269759 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered intravenously 2 hours before endotoxin challenge
Number of subjects: 16
Study 9269759 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered subcutaneously 24 hours before endotoxin challenge
Number of subjects: 16
Study 9269759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8329254 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120
Study 8329254 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaveretum 10 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120
Study 8329254 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120
Study 8329254 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaveretum 10 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120
Study 2883393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a attenuated Salmonella typhi oral vaccine in an enteric‐coated formulation
Number of subjects: 109000
Study 2883393 — intervention group
Group type: COMPARATOR
Intervention: Ty21a vaccine in gelatin capsules with sodium bicarbonate
Number of subjects: 109000
Study 2883393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a vaccine
Number of subjects: 109000
Study 28880698 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP) intervention
Number of subjects: 36
Study 28880698 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 26438518 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 300 mg calcium per day (Group A)
Number of subjects: 210
Study 26438518 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 600 mg calcium per day (Group B)
Number of subjects: 210
Study 26438518 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 900 mg calcium per day (Group C)
Number of subjects: 210
Study 26438518 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study 25251201 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable, extended-release naltrexone
Number of subjects: 80
Study 25251201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23063084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g IV (GrAP)
Number of subjects: 310
Study 23063084 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (GrAPn)
Number of subjects: 310
Study 20173194 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention encoding
Number of subjects: 0
Study 20173194 — intervention group
Group type: COMPARATOR
Intervention: Behavioral practice
Number of subjects: 0
Study 17766429 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV model for predicting 30-day survival
Number of subjects: 537
Study 17766429 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV model for predicting independent survival at 6 months
Number of subjects: 537
Study 17766429 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV model's ROC curve for 30-day survival
Number of subjects: 537
Study 17766429 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV model's ROC curve for independent survival at 6 months
Number of subjects: 537
Study 17766429 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the SSV model
Number of subjects: 537
Study 15530588 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Number of subjects: 2408
Study 15530588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (smoking reduction groups)
Number of subjects: 2408
Study 15530588 — intervention group
Group type: COMPARATOR
Intervention: Background population (control)
Number of subjects: 2408
Study 15530588 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (assumed control)
Number of subjects: 2408
Study 15530588 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of at least 5 g
Number of subjects: 2408
Study 15530588 — intervention group
Group type: EXPERIMENTAL
Intervention: Halving of tobacco consumption
Number of subjects: 2408
Study 12180276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (50-300 mg/day)
Number of subjects: 36
Study 12180276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (100-400 mg/day)
Number of subjects: 36
Study 12417161 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO) application
Number of subjects: 0
Study 12417161 — intervention group
Group type: COMPARATOR
Intervention: Conventional closed methods
Number of subjects: 0
Study 9666536 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted low-dose warfarin (INR 1.5-2.0)
Number of subjects: 0
Study 9666536 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 0
Study 8582151 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antiplatelet regimens (including aspirin)
Number of subjects: 769
Study 8582151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 2765346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study 2765346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 20
Study 950457 — intervention group
Group type: EXPERIMENTAL
Intervention: Outplacement planning
Number of subjects: 84
Study 950457 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 84
Study 950457 — intervention group
Group type: EXPERIMENTAL
Intervention: Outplacement planning (released)
Number of subjects: 84
Study 950457 — intervention group
Group type: EXPERIMENTAL
Intervention: Outplacement planning (not released)
Number of subjects: 84
Study 950457 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient planning (not released)
Number of subjects: 84
Study 31550951 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscope-guided lightwand (Group VL)
Number of subjects: 318
Study 31550951 — intervention group
Group type: COMPARATOR
Intervention: Single lightwand (Group L)
Number of subjects: 318
Study 28579423 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels
Number of subjects: 3138
Study 28579423 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels (without kidney measures)
Number of subjects: 3138
Study 25714602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EAC)
Number of subjects: 60
Study 25714602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 60
Study 25714602 — intervention group
Group type: COMPARATOR
Intervention: SHAM acupuncture
Number of subjects: 60
Study 23691833 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional aids designed with human factors principles
Number of subjects: 60
Study 23691833 — intervention group
Group type: COMPARATOR
Intervention: Standard manufacturer-provided visual aids (Control)
Number of subjects: 60
Study 23691833 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional aids
Number of subjects: 60
Study 21787508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper 0.04
Number of subjects: 45
Study 21787508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper 0.06
Number of subjects: 45
Study 21787508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper 0.08
Number of subjects: 45
Study 19338452 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d)
Number of subjects: 79
Study 19338452 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 79
Study 16777382 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (1%, w/v)
Number of subjects: 50
Study 16777382 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 15085362 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP/C-629A polymorphism (A-allel carriers)
Number of subjects: 1968
Study 15085362 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP genotypes
Number of subjects: 1968
Study 15085362 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP/C-629A polymorphism
Number of subjects: 1968
Study 15085362 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for classical risk factors
Number of subjects: 1968
Study 15085362 — intervention group
Group type: COMPARATOR
Intervention: Controlling for HDL concentration
Number of subjects: 1968
Study 11213861 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program addressing breast cancer screening schedules and modalities, including training on breast self-examination (BSE), clinical breast examination (CBE), and mammography.
Number of subjects: 140
Study 9299674 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making strategy A (combination of disease indices and serum concentrations of orosomucoid)
Number of subjects: 88
Study 9299674 — intervention group
Group type: COMPARATOR
Intervention: Decision-making strategy B (disease indices only)
Number of subjects: 88
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat A1 osteotomy (OT)
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep A1 osteotomy (OT)
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 osteotomy with partial defect
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed intertrochanteric osteotomy (OT)
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed subtrochanteric osteotomy (OT)
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 osteotomy with complete medial defect using gamma nail
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 osteotomy with complete medial defect using DHS after valgisating displacement OT
Number of subjects: 301
Study 8117512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtrochanteric resection and double plate compound osteosynthesis (DPCO)
Number of subjects: 301
Study 8117512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OT)
Number of subjects: 301